Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial

13 Mar 2024

Abstract excerpt

BACKGROUND: This phase 1 trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1647, a messenger RNA (mRNA)-based cytomegalovirus (CMV) vaccine, in CMV-seronegative and -seropositive adults. METHODS: Participants were randomly assigned to receive 30, 90, 180, or 300 µg of mRNA-1647 or placebo on a 0-, 2-, and 6-month schedule and followed for 12 months after the last dose. RESULTS: A total of 154...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38478705
DOI: 10.1093/infdis/jiae114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical TrialPMID 38478705Read ↗

Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adultsSemantic proximity Read ↗

Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical StudySemantic proximity Read ↗

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 VaccineSemantic proximity Read ↗

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccinesSemantic proximity Read ↗

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read ↗

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseasesSemantic proximity Read ↗

A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in AdultsSemantic proximity Read ↗

mRNA-based modalities for infectious disease managementSemantic proximity Read ↗

In Gratitude for mRNA VaccinesSemantic proximity Read ↗

Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infectionSemantic proximity Read ↗

RNA-based vaccines and innate immune activation: Not too hot and not too coldSemantic proximity Read ↗

mRNA vaccines in the prevention and treatment of diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.